Viking Return On Capital Employed from 2010 to 2024

VKTX Stock  USD 52.59  0.96  1.86%   
Viking Therapeutics Return On Capital Employed yearly trend continues to be fairly stable with very little volatility. Return On Capital Employed will likely drop to -0.3 in 2024. During the period from 2010 to 2024, Viking Therapeutics Return On Capital Employed regression line of annual values had significance of  0.95 and arithmetic mean of (0.43). View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
(0.29)
Current Value
(0.30)
Quarterly Volatility
0.78509193
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 277.4 K, Interest Expense of 83.6 K or Selling General Administrative of 38.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.29. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Viking Therapeutics over the last few years. It is Viking Therapeutics' Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Very volatile
   Return On Capital Employed   
       Timeline  

Viking Return On Capital Employed Regression Statistics

Arithmetic Mean(0.43)
Coefficient Of Variation(183.10)
Mean Deviation0.57
Median(0.28)
Standard Deviation0.79
Sample Variance0.62
Range3.1157
R-Value(0.02)
Mean Square Error0.66
R-Squared0.0003
Significance0.95
Slope(0)
Total Sum of Squares8.63

Viking Return On Capital Employed History

2024 -0.3
2023 -0.29
2022 -0.48
2021 -0.28
2020 -0.17
2019 -0.12
2018 -0.0879

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Return On Capital Employed, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Capital Employed(0.29)(0.30)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.